Biotech · Private company
COMPASS Pathways
Track this companyFree. Adds COMPASS Pathways to your Dealase workspace and tells you when its record changes.
Clinical trials164 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- COMP360 psilocybinPhase 3 · PTSD - Post Traumatic Stress DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PsilocybinPhase 3 · Treatment Resistant DepressionClinicalTrials.gov · fetched Nov 12, 2026
- PsilocybinPhase 2 · Anorexia NervosaClinicalTrials.gov · fetched Nov 12, 2026
- PsilocybinPhase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PsilocybinPhase 2 · Post Traumatic Stress DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderPHASE2_PHASE3 · RECRUITING · started Sep 14, 2026ClinicalTrials.gov NCT07570654 · fetched Nov 12, 2026
- The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderPHASE3 · RECRUITING · started Sep 10, 2024ClinicalTrials.gov NCT06247839 · fetched Nov 12, 2026
- Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRDPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 14, 2023ClinicalTrials.gov NCT05711940 · fetched Nov 12, 2026
- A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2023ClinicalTrials.gov NCT05733546 · fetched Nov 12, 2026
- Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDPHASE3 · COMPLETED · started Jan 24, 2023ClinicalTrials.gov NCT05624268 · fetched Nov 12, 2026
- Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyPHASE2 · COMPLETED · started Oct 12, 2022ClinicalTrials.gov NCT05481736 · fetched Nov 12, 2026
- The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDDPHASE2 · WITHDRAWN · started Sep 15, 2022ClinicalTrials.gov NCT05381974 · fetched Nov 12, 2026
- The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderPHASE2 · COMPLETED · started Jun 10, 2022ClinicalTrials.gov NCT05312151 · fetched Nov 12, 2026
- The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationPHASE2 · COMPLETED · started Mar 28, 2022ClinicalTrials.gov NCT05220410 · fetched Nov 12, 2026
- Evaluation of Psilocybin in Anorexia Nervosa: Safety and EfficacyPHASE2 · COMPLETED · started May 1, 2021ClinicalTrials.gov NCT04661514 · fetched Nov 12, 2026
- The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.PHASE2 · UNKNOWN · started Mar 1, 2021ClinicalTrials.gov NCT04433845 · fetched Nov 12, 2026
- An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)PHASE2 · UNKNOWN · started Mar 1, 2021ClinicalTrials.gov NCT04433858 · fetched Nov 12, 2026
- Safety and Efficacy of Psilocybin for Body Dysmorphic DisorderPHASE2 · COMPLETED · started Feb 26, 2021ClinicalTrials.gov NCT04656301 · fetched Nov 12, 2026
- The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant DepressionPHASE2 · COMPLETED · started Aug 10, 2020ClinicalTrials.gov NCT04739865 · fetched Nov 12, 2026
- Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)COMPLETED · started Jul 20, 2020ClinicalTrials.gov NCT04519957 · fetched Nov 12, 2026
- The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionPHASE2 · COMPLETED · started Mar 1, 2019ClinicalTrials.gov NCT03775200 · fetched Nov 12, 2026